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Abstract
Selective blockade of Kv1.3 channels in effector memory T (TEM) cells was validated to ameliorate autoimmune or
autoimmune-associated diseases. We generated the antibody directed against one peptide of human Kv1.3 (hKv1.3)
extracellular loop as a novel and possible Kv1.3 blocker. One peptide of hKv1.3 extracellular loop E3 containing 14 amino
acids (E314) was chosen as an antigenic determinant to generate the E314 antibody. The E314 antibody specifically
recognized 63.8KD protein stably expressed in hKv1.3-HEK 293 cell lines, whereas it did not recognize or cross-react to
human Kv1.1(hKv1.1), Kv1.2(hKv1.2), Kv1.4(hKv1.4), Kv1.5(hKv1.5), KCa3.1(hKCa3.1), HERG, hKCNQ1/hKCNE1, Nav1.5 and
Cav1.2 proteins stably expressed in HEK 293 cell lines or in human atrial or ventricular myocytes by Western blotting analysis
and immunostaining detection. By the technique of whole-cell patch clamp, the E314 antibody was shown to have a
directly inhibitory effect on hKv1.3 currents expressed in HEK 293 or Jurkat T cells and the inhibition showed a
concentration-dependence. However, it exerted no significant difference on hKv1.1, hKv1.2, hKv1.4, hKv1.5, hKCa3.1, HERG,
hKCNQ1/hKCNE1, L-type Ca
2+ or voltage-gated Na
+ currents. The present study demonstrates that the antibody targeting
the E314 peptide of hKv1.3 pore region could be a novel, potent and specific hKv1.3 blocker without affecting a variety of
closely related Kv1 channels, KCa3.1 channels and functional cardiac ion channels underlying central nervous systerm (CNS)
disorders or drug-acquired arrhythmias, which is required as a safe clinic-promising channel blocker.
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Introduction
Over the last decade, the voltage-gated potassium channel,
Kv1.3, with its distribution largely in immunocytes and certain
areas in the brain [1,2], has received much attention and gained a
vast body of compelling evidence on its modulation of specified
lymphocyte subsets. In autoimmune diseases including multiple
sclerosis, type-1 diabetes, psoriasis, rheumatoid arthritis, transplant
rejection, graft-versus-host disease, SjO ¨ gren’s syndrome, and
systemic lupus erythematosus, effector memory T cells contribute
greatly to inflamed injuries [3–13]. Focusing on the role of Kv1.3
in the modulation of lymphocyte subsets, a series of studies reveal
that the presence of Kv1.3 controls activation and proliferation of
autoreactive effector lymphocytes [11,14–17]. Inhibition of Kv1.3
channels leads to the down-regulation of TEMs activities, which
was validated to ameliorate autoimmune diseases in animal models
[18–21]. These data suggest that Kv1.3 represents a novel target
for the treatment of autoimmune diseases. And as a promising
therapeutic approach, selective blockade of Kv1.3 attracts more
attention in seeking potent Kv1.3 blockers.
Small molecules or peptide toxins have been explored for
selective Kv1.3 blockers [22–35], however, quite a few of them
lack ion channel selectivity and exhibit a broad pattern of channel
blockers [24,36,37]. In addition to Kv1.3 blockade, these
chemicals block other homologous K
+ channels as well as Na
+
or Ca
2+ channels [27]. Thus blockade of the channels underlies
fatal arrhythmias or central nervous systerm(CNS) disorders.
Antibodies have the characteristics of high affinity and
specificity. We herein generated the antibody directed against
one peptide of human Kv1.3 extracellular loop as a novel and
specific Kv1.3 blocker.
Results
The E314 antibody generation
The E314 peptide containing 14 amino acids is located at the
external end of hKv1.3 pore region. The amino acid sequence is
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e36379shown as follows: Glu- Ala- Asp- Asp- Pro- Thr- Ser- Gly- Phe-
Ser- Ser- Ile- Pro- Asp (China patent application num-
ber:201110044416.X Fig. 1A). By immunizing rabbits with the
hapten, we generated the polyclonal antibody against the hKv1.3
E314 peptide with a high titre. After three immunizations, the
antibody titre in serum was markedly boosted and reached a high
and stable level at the termination of the immunization (Fig. 1B).
The E314 antibody specifically recognizes or binds to
human Kv1.3 protein
By immunostaining, we observed the binding of the E314
antibody diluted at 1:200 to plasma membranes respectively in
raw HEK 293 cells (Fig. 2B), HEK 293 cell lines stably expressing
hKv1.3 (Fig. 2A), hKv1.1, hKv1.2, hKv1.4, hKCa3.1, HERG and
hKCNQ1/hKCNE1 proteins (Fig. 2C, D, E, F, G and H) and
human atrial myocytes (Fig. 2I). The results indicated that there
was only green fluorescence detected on plasma membranes in
HEK 293 cells stably expressing hKv1.3 channels and the
fluorescence signals could be completely blocked by the E314
antibody preincubated with an excess of the E314 peptide (Fig. 2J).
By Western blotting, we analyzed the E314 antibody specific
recognition. As illustrated in Figure 2, the E314 antibody showed a
specific recognition of hKv1.3 protein. The E314 antibody diluted
at 1:1000 recognized 63.8KD hKv1.3 protein stably expressed in
HEK 293 cells (Fig. 2K lane 1), whereas it was not able to
recognize identical molecular weight protein in raw HEK 293 cells
or 56KD hKv1.1, 70–80KD hKv1.2, 68KD hKv1.4, 45KD
hKCa3.1, 145/155KD HERG, 120KD hKCNQ1 protein stably
expressed in HEK 293 cells (Fig. 2K lane 2, 3, 4, 5, 6, 7 and 8).
Specific recognition of hKv1.3 protein could be completely
blocked by the E314 antibody preincubated with an excess of
the E314 peptide (Fig. 2K lane 9). Furthermore in human atrial or
ventricular myocytes, we demonstrated that the E314 antibody did
not recognize 75KD Kv1.5 protein, 145/155KD HERG protein,
120KD hKCNQ1 protein, 220KD Nav1.5 protein or 190KD
Cav1.2 protein comprising chiefly of L-type Ca
2+ channel (Fig. 2L).
The E314 antibody inhibits human Kv1.3 currents stably
expressed in HEK 293 cells
Using the whole-cell patch clamp technique, we tested the
ability of the E314 antibody inhibiting hKv1.3 currents stably
expressed in HEK 293 cells. The hKv1.3 currents were gradually
inhibited after addition of the 300 nM E314 antibody to the
external solution and the inhibition reached about 55% steady-
state level in 10–15 minutes whcih was not reversible by washout
(e.g., Figure S1 for the first supporting information figure). To
obtain potent binding between the antigen and the antibody, cells
stably expressing hKv1.3 channels were preincubated with the
peptide-specific polyclonal antibody for two hours at 36uC and
then superfused to wash off unbound antibodies, as undergone in
immunoexperiments.
IKv1.3 was elicited by the 300-ms voltage steps from 280 mV to
between 260 and +60 mV (as shown in the inset) in HEK 293 cells
stably expressing hKv1.3 channel and IKv1.3 was absent in raw HEK
293 cells (Fig. 3A). The E314 antibody with a concentration of 300,
150,75, or 37.5 nM significantly decreased hKv1.3 current densities
at test potentials from 230 to +60 mV and the inhibition was
stronger at more positive potentials. The inhibition showed a
concentration-dependence (Fig. 3B). At the depolarizing pulse
+50 mV, the E314 antibody with concentrations ranging from
37.5 nM to 300 nM inhibited human Kv1.3 current densities
respectively by 66%, 84%, 88% or 94% (0.1095160.0165 nA/pF,
0.0528560.01825 nA/pF, 0.0384860.01049 nA/pF, 0.019146
0.0043 nA/pF, vs 0.3209460.06573 nA/pF,P,0.001 vs control)
(Fig. 3C).
To verify that the E314 antibody does bind to the external end
of hKv1.3 pore region where the E314 peptide was generated and
that the inhibiting effect is attributed to the binding of the E314
antibody to the hKv1.3 channel, we recorded hKv1.3 currents in
the presence of the 300 nM E314 antibody that was preincubated
with an excess of the E314 peptide. Supposed that supression was
due to binding of the antibody to the peptide in external pore
region, the inhibition should be prevented by preincubation with
the peptide. As shown in Figure 3B and 3C, the inhibiting effect of
the E314 antibody on IKv1.3 was abolished after preincubation
with the peptide, which indicated that the inhibition was due to
specific binding of the E314 antibody to the E314 peptide around
hKv1.3 pore region.
Voltage dependence of hKv1.3 channel activation (I/Imax) was
determined by normalizing IKv1.3 in the absence and presence of
the 300 nM E314 antibody. Data were fitted to a Boltzmann
distribution to obtain the half-activation voltage (V0.5) and the
Figure 1. The E314 peptide selection and the E314 antibody
generation. (A) Six-membrane spanning (S1–S6) of hKv1.3 channel a
subunit and pore region between S5 and S6 was depicted by
hydrophilicity analysis of its constituent amino acid aligment. The
E314 peptide located at pore region was selected according to amino
acid antigenic index. (B) The E314 antibody titre was assayed by
enzymelinked immunosorbent assay (ELISA). The E314 antibody wth a
high titre was generated after 5 immunizations.
doi:10.1371/journal.pone.0036379.g001
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positively shifted by 10.2 mV (from 8.560.8 mV of control to
18.761.0 mV of the E314 antibody, n=6, P,0.01) by the
300 nM E314 antibody, and the slope factor was slightly
decreased (17.860.2 mV for control, 15.860.9 mV for the
E314 antibody, P.0.05) (Fig. 3D). The E314 antibody affects
the activation gating of hKv1.3 channels.
The E314 antibody inhibits human Kv1.3 currents in
Jurkat T cells
To further study the ability of the E314 antibody inhibiting
hKv1.3 currents, we also tested the effect of the anibody on human
leukemia T cell line, Jurkat E6-1 cells. IKv1.3 expressed in Jurkat T
cells preincubated with the E314 antibody for two hours at 36uC
was recorded with the voltage protocol as described previously in
the absence and presence of the 300 nM E314 antibody (Fig. 4A
and B). The 300 nM E314 antibody significantly decreased
hKv1.3 current densities at test potentials from 230 to +60 mV
and the inhibition was stronger at more positive potentials
(Fig. 4C). At the depolarizing pulse +50 mV, the 300 nM E314
antibody inhibited hKv1.3 current densities by 90%
(3.4955260.89790 nA/pF vs 34.5790862.21566 pA/
pF,P,0.001) (Fig. 4D).
Figure 2. The E314 antibody specific recognition of human Kv1.3 protein by immunostaining and Western blotting. Plasma
membrane was stained with green fluorescence in HEK 293 cells stably expressing hKv1.3 channels (A), whereas no membrane fluorescence was
detected in raw HEK 293 cells (B), HEK 293 cells stably expressing hKv1.1 channels (C), hKv1.2 channels (D), hKv1.4 channels (E), hKCa3.1 channels (F),
HERG channels (G), hKCNQ1/hKCNE1 channels (H), human atrial myocytes (I), or HEK 293 cells stably expressing hKv1.3 channels exposed to the E314
antibody preincubated with an excess of the E314 peptide (J). Nuclei were stained with blue fluorescence by using DAPI labelling. In HEK 293 cells
stably expressing hKv1.3 protein, the E314 antibody specifically recognized 63.8KD protein (K lane 1), whereas the recognition was absent in raw HEK
293 cells (K lane 2), HEK 293 cells stably expressing hKv1.1 protein (K lane 3), hKv1.2 protein (K lane 4), hKv1.4 protein (K lane 5), hKCa3.1 protein (K
lane 6), HERG protein (K lane 7), hKCNQ1/hKCNE1 protein (K lane 8) or when the E314 antibody was preincubated with an excess of the E314 peptide
(K lane 9). In human atrial or ventricular myocytes, the E314 antibody did not recognize 145KD/155KD HERG protein, 120KD hKCNQ1 protein, 220KD
Nav1.5 protein or 190KD Cav1.2 protein (L).
doi:10.1371/journal.pone.0036379.g002
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PLoS ONE | www.plosone.org 3 April 2012 | Volume 7 | Issue 4 | e36379Figure 3. The E314 antibody inhibits human Kv1.3 currents stably expressed in HEK 293 cells. (A) IKv1.3 traces were activated at 0.1 Hz
upon 250 ms voltage steps to between 260 and +60 mV (10-mV increment) from 280 mV with tail current at 250 mV in HEK 293 cells stably
expressing hKv1.3 currents. The current was absent in raw HEK 293 cells. (B) The E314 antibody inhibited hKv1.3 currents in a concentration-
dependent manner at test potentials from 230 to +60 mV and the inhibition was abolished by the E314 antibody preincubated with an excess of the
E314 peptide, as shown in I–V relationship. (C) At depolarizing pulse +50 mV, the E314 antibody ranging from 37.5 to 300 nM inhibited hKv1.3
current density respectively by 66% (P,0.001), 84% (P,0.001), 88% (P,0.001) and 94% (P,0.001). (D) Steady-state activation relationships of hKv1.3
channels were fitted to a Boltzmann distribution: y=1/{1+exp[(Vm-V0.5)/S]}, where Vm is the membrane potential, V0.5 is the midpoint, and S is the
slope. V0.5 for activation conductance of IKv1.3 was 8.560.8 mV in control, and 18.761.0 mV in the 300 nM E314 antibody (n=6, P,0.05). S was
respectively 17.860.2 mV or 15.860.9 mV, for control and the 300 nM E314 antibody (P.0.05).
doi:10.1371/journal.pone.0036379.g003
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IKv1.2,I Kv1.4,I Kv1.5,I KCa3.1,I HERG,I hKCNQ1/hKCNE1, ICaL or INa
To further verify the specificity of the E314 antibody, we
examined the effect of E314 antibody on other closely related Kv1-
family channels, functional cardiac ion channels and KCa3.1
channel which is another important potassium channel expressed
in T lymphocytes. Human atrial myocytes were used to observe
the effect of E314 on IKv1.5,I CaL or INa and the effect of E314 on
IKv1.1,I Kv1.2,I Kv1.4,I KCa3.1,I HERG or IhKCNQ1/hKCNE1 was
studied in HEK 293 cells stably expressing hKv1.1 channel,
hKv1.2 channel, hKv1.4 channel, hKCa3.1 channel, HERG
channel or hKCNQ1/hKCNE1 channels. Voltage-dependent
IKv1.1,I Kv1.2,I Kv1.4,I Kv1.5,I KCa3.1,I HERG,I hKCNQ1/hKCNE1,I CaL
or INa were elicited respectively by the voltage protocol shown in
the inset of Figure 5, 6 and 7. In contrast to its effect on hKv1.3
currents, exposure of the 300 nM E314 antibody yielded limited
effects on IKv1.1,I Kv1.2,I Kv1.4,I Kv1.5,I KCa3.1,I HERG,I hKCNQ1/
hKCNE1,I CaL or INa at all test potentials. At the depolarizing pulse
+50 mV for IKv1.1,I Kv1.2,I Kv1.4 and IKv1.5, +40 mV for IKCa3.1,
IHERG.tail and IhKCNQ1/hKCNE1.step, 235 mV for maximal INa,
+10 mV for maximal ICaL, the 300 nM E314 antibody caused no
statistically significant effect on peak value of each current
including IKv1.1 (0.5160.07 nA/pF vs 0.5460.08 nA/pF,
P.0.05), IKv1.2 (0.1360.02 nA/pF vs 0.1560.02 nA/pF,
P.0.05), IKv1.4 (0.1860.01 nA/pF vs 0.1960.01 nA/pF,
P.0.05), IKv1.5 (8.1360.90 pA/pF vs 8.2561.03 pA/pF,
P.0.05), IKCa3.1 (0.09 nA/pF vs 0.10 nA/pF, P.0.05), IHERG.tail
(38.3865.02 pA/pF vs 39.5865.13 pA/pF, P.0.05), IhKCNQ1/
hKCNE1.step (0.2460.02 nA/pF vs 0.2760.01 nA/pF, P.0.05),
ICaL (16.0363.23 pA/pF vs 16.8461.8 pA/pF, P.0.05) and INa
(37.3366.67 pA/pF vs 38.5566.73 pA/pF, P.0.05). (Fig. 5, 6
and 7).
Discussion
Autoimmune diseases or autoimmune-associated diseases afflict
millions of people in the world. Overreaction of immune activities
plays a pivotal role in the pathogenesis of these diseases [11]. Thus
immunosuppression therapy is of broad use in the management of
autoimmune diseases [20,38]. However pleiotropic actions of
immunosuppressants clinically available such as methylpredniso-
lone limit therapeutic values [39,40]. For patients, more specific
immunosuppression would help to ameliorate disease with less
adverse or side effects [24,41]. In recent years, selective blockade
of Kv1.3 in TEM cells has exhibited the potential of specific
inhibition of T lymphocyte subsets and leaves protective immunity
unharmed, which encourages increasing efforts to explore selective
or specific Kv1.3 blockers [36,41–43]. In this study, we presented
a novel, potent and specific Kv1.3 blocker.
Unlike the heteromultimeric Kv1.3 channel expressed in
neurons, Kv1.3-containing homotetramers in lymphocytes com-
prise 4 identical subunits [44,45]. We expressed the identical
subunits in a stable HEK 293 cell lines, which represents Kv1.3
channels expressed in lymphocytes. The antibody designed
targeting one subunit would be possible to exert its effect on the
Kv1.3 channel. By computing the antigenic index and hydrophi-
licity of hKv1.3 constituent amino acid aligment, we selected an
antigenic peptide that is located at the external end of the pore
region which has been successfully used to generate polyclonal
antibodies against several ion channels [46,47]. The peptide
location was indicated by immunostaining of the E314 antibody
binding. The pore region is the way mediating K
+ efflux and
determines ion permeability [48,49]. The E314 antibody blocks
the pore region from the external end with a large interacting
surface, which utilizes a ‘‘cork in the bottle’’ strategy exemplified
by peptide toxins, covering and plugging the external end [24,42].
The external block by the E314 antibody yields the K
+
Figure 4. The E314 antibody inhibits IKv1.3 in Jurkat T cells. IKv1.3 expressed in Jurkat T cells was recorded with the voltage protocol as
described previously in the absence (A) and presence (B) of the 300 nM E314 antibody. (C) I–V relationship of IKv1.3 in the presence of the 300 nM
E314 antibody at test potentials from 230 to +60 mV. (D) At depolarizing pulse +50 mV, the 300 nM E314 antibody inhibited hKv1.3 current densities
by 90% (P,0.001).
doi:10.1371/journal.pone.0036379.g004
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contrast with the internal block by small molecules which is greatly
affected by gating-associated conformational changes and state-
dependent [37,50]. The external block gives the E314 antibody
more potency. In this study, the E314 antibody in nanomolar
concentrations showed a strong inhibition, comparable to some
selective kv1.3 blockers [38,51,52].
In clinics, a variety of drugs including immunosuppressants can
increase the risk of drug-acquired arrhythmias due to the impact
on functional cardiac ion channels [53–56]. It is documented that
drug binding sites among Kv1.3, Kv1.5, HERG and hKCNQ1/
hKCNE1 channels are conservative [21,36,43,57]. The conserva-
tion hinders some Kv1.3-blocking candidates from being devel-
oped into good drugs. Thus, to prevent the occurrence of drug-
acquired arrhythmias, the ICH E14 and S7B guidance issued by
FDA calls for the assessment of the potential of any drug to delay
cardiac repolarisation [58–60]. Besides, loss function of closely
related Kv1 channels, such as Kv1.1 or Kv1.2 is able to result in
CNS disorders [61,62]. By blast, we found that there is a maximal
homology between the hKv1.3-E314 peptide and the correspond-
ing peptides of hKv1.1, hKv1.2, hKv1.4 or hKv1.5. In addition
KCa3.1 channels in T lymphocytes might be of importance for
immune-mediated side-effects [63]. Recently the tandem of pore
domains in a weak inwardly rectifying potassium channel-related
acid-sensitive potassium channels (TASK1–3) have been found to
be expressed in the nervous system, T lymphocytes and heart and
play important role in cardiac repolarization, autoimmune
inflammation, cancer development and CNS disorders [64–66].
Figure 5. No significant effect of the E314 antibody on IKv1.1,I Kv1.2,I Kv1.4 or IKv1.5. IKv1.1,I Kv1.2 and IKv1.4 stably expressed in HEK 293 cells
were recorded with the voltage protocol described as IKv1.3 and IKv1.5 was elicited at 1 Hz with a 100-ms prepulse to +40 mV to inactivate Ito1,
followed by 150-ms test pulses from 250 to between 240 and +60 mV after a 10-ms interval, then to 230 mV in human atrial myocytes. There was
no pronounced alteration of IKv1.1 (A, B and C), IKv1.2 (E, F and G), IKv1.4 (I, J and K) or IKv1.5 (M, N and O) at all test potentials in the presence of the
300 nM E314 antibody. At depolarizing pulse +50 mV for IKv1.1,I Kv1.2,I Kv1.4 or IKv1.5, the E314 antibody caused no significant effect on IKv1.1 (D), IKv1.2
(H), IKv1.4 (L) or IKv1.5 (P) (P.0.05).
doi:10.1371/journal.pone.0036379.g005
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the E314 antibody as a potential candidate for specific Kv1.3
blockers on functional cardiac ion channels, closely related Kv1
channels, KCa3.1 channels and TASK1–3 channels.
Immunoexperiment results indicate that the E314 antibody can
specifically recognize hKv1.3 protein, whereas it is not able to
recognize or cross-react to hKv1.1, hKv1.2, hKv1.4, hKv1.5,
hKCa3.1, HERG, hKCNQ1/hKCNE1 or human Nav1.5,
Cav1.2 proteins. By the patch clamp technique, we demonstrated
that the E314 antibody with a high concentration exhibits no
significant effect on these closely related Kv1 channels, KCa3.1
channels or functional cardiac ion channels. By blast analysis, we
found that there is no homology between Kv1.3 and TASK1–3
channels. All the results indicate that the E314 antibody is able to
function as a novel specific hKv1.3 blocker without worries about
its potential proarrhythmias, immune-mediated side-effects or
CNS disorders, which is required as a safe clinic-promising
channel blocker.
Based on the E314 antibody generation regimen, one
monoclonal antibody with more affinity and specificity or a
vaccine targeting hKv1.3 E314 peptide, which can serve as a novel
hKv1.3 blocker to inhibit autoreactive T lymphocyte activities,
would probably be developed as a novel drug for the treatment of
autoimmune diseases or autoimmune-associated diseases. The
attractiveness arises from the excellent track record of several
monoantibodies and a vaccine, such as infliximab [67], adalimu-
mab [68], natalizumab [69], Anti-IL-17A vaccine [70], which is
typical of targeting biological therapy, gradually superior to
traditional immunosuppressants.
Materials and Methods
Ethics statement
In this study, the procedure of obtaining human atrial and
ventricle specimens from patients receiving cardiac surgery
conforms to the principles outlined in the Declaration of Helsinki.
The study was approved by the Ethics Committee of Tongji
Figure 6. No significant effect of the E314 antibody on IHERG,I hKCNQ1/hKCNE1,I Na or ICaL. IHERG,I hKCNQ1/hKCNE1 stably expressed in HEK 293
cells, INa and ICaL in human atrial myocytes were recorded with the voltage protocol shown in the inset in the absence and presence of the 300 nM
E314 antibody. There was no pronounced alteration of IHERG (A, B and C), IhKCNQ1/hKCNE1 (E, F and G), ICaL (I, J and K) or INa (M, N and O) at all test
potentials in the presence of the 300 nM E314 antibody. At depolarizing pulse +40 mV for IHERG.tail,I hKCNQ1/hKCNE1.step, +10 mV for ICaL or 235 mV for
INa, the E314 antibody caused no significant effect on IHERG.tail (D), IhKCNQ1/hKCNE1.step (H), ICaL (L) or INa (P) (P.0.05).
doi:10.1371/journal.pone.0036379.g006
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Technology and patients provided written informed consent.
In this study, the animal use and care protocol was approved by
the Ethical Committee on Animal Experimentation of Tongji
Medical College, Huazhong University of Science and Technol-
ogy (Approval ID: 00009678). All surgery was performed under
sodium pentobarbital anesthesia, and every effort was made to
minimize suffering.
Antibody generation
One extracellular peptide located at E3 loop between hKv1.3
spanning S5 and S6 was selected as an antigenic determinant
according to its constituent amino acid antigenic index calculated
by the software DNAStar and the corresponding amino acid
alignment was synthesized by PSSM8 Peptide Synthesizer
(Shimadzu, Japan). Adult male New Zealand white rabbits from
the Center of Experimental Animals (Tongji Medical College,
Huazhong University of Science and Technology, China) were
fortnightly immunized by subcutaneous injection of a mixture of
the synthetic peptide conjugated with bovine serum albumin (BSA)
and complete or incomplete Freund’s adjuvant. Rabbits receiving
sham immunization with a mixture of physiological saline
conjugated with complete or incomplete Freund’s adjuvant were
as a control. Serum was collected before each immunization and
the rabbits were sacrificed on 63 d of the experiment. Harvested
serum were screened by enzymelinked immunosorbent assay
(ELISA) and purified on a protein A column (UNOsphere SUPrA
Affinity Cartridge, Bio-Rad, US). The E314 antibody was
additionally purified on an peptide-affinity column (GL Biochem
Ltd, Shanghai, China).
Cell culture and establishment of cell lines
HEK 293 cells were purchased from the American Type
Culture Collection (ATCC Manassas, VA, USA) and grown in
Dulbecco’s modified Eagle medium (DMEM, Invitrogen, Carls-
bad, CA) supplemented with 10% fetal bovine serum (Invitrogen,
Carlsbad, CA) in 5% CO2 and 95% air at 37uC.
Jurkat-T cells (clone E6-1) were purchased from the China
Center for Type Culture Collection (CCTCC Wuhan, China) and
grown in RPMI 1640 media (Invitrogen, Carlsbad, CA)
supplemented with 10% fetal bovine serum (Invitrogen), 1 mM
sodium pyruvate (Invitrogen) and 1% penicillin/streptomycin
(Invitrogen) in 5% CO2 and 95% air at 37uC.
The vector of hKv1.3/pCI-neo generously provided by Dr.
Garcia Maria (Merck & Co. Inc, West Point, PA) was transfected
into HEK 293 cells using FuGENEH HD (Roche, Germany)
following the manufacturer’s instructions. The HEK 293 cell line
stably expressing hKv1.3 channels were selected in 800 mg/ml
G418 (Invitrogen, Carlsbad, CA) and was maintained in DMEM
containing 400 mg/ml G418.
HEK 293 cell lines stably expressing hKv1.1, hKv1.2, hKv1.4,
HERG or hKCNQ1/hKCNE1, KCa3.1 channels were estab-
lished in a similar way. The vector of HERG/pcDNA3 generously
provided by Dr. G. Robertson (University of Wisconsin, Madison,
WI, USA) was transfected into HEK 293 cells using Attractene
(QIAGEN, US). The vector of hKCNQ1/pCEP4 was a generous
Figure 7. No significant effect of the E314 antibody on IKCa3.1. IKCa3.1 stably expressed in HEK 293 cells was elicited by 200-ms voltage ramps
from 2120 to 40 mV applied every 10 s in the absence and presence of the 300 nM E314 antibody. There was no pronounced alteration of IKCa3.1 (A
and B) at all test potentials in the presence of the 300 nM E314 antibody. At depolarizing pulse +40 mV, the E314 antibody caused no significant
effect on IKCa3.1 (D) (P.0.05).
doi:10.1371/journal.pone.0036379.g007
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Kong, China) and human KCNE1, Kv1.1, Kv1.2 and Kv1.4,
KCa3.1 cDNAs, synthesized by the corporation of FulenGene
(China) were subcloned into pcDNA3 vector (Invitrogen, CA).
The vectors of hKCNQ1/pCEP4 and hKCNE1/pcDNA3 were
co-transfected into HEK 293 cells using Attractene (QIAGEN,
US). The vectors of hKv1.1/pcDNA3, hKv1.2/pcDNA3,
hKv1.4/pcDNA3 and hKCa3.1/pcDNA3 were transfected into
HEK 293 cells using Attractene (QIAGEN, US) seperately. After
selection in 800 mg/ml G418 or 200 mg/ml hygromycin (Roche,
Germany), HEK 293 cell lines stably expressing hKv1.1, hKv1.2,
hKv1.4, hKCa3.1, HERG or hKCNQ1/hKCNE1 channels were
maintained in DMEM containing 400 mg/ml G418 or 100 mg/ml
hygromycin.
Human atrial myocyte isolation
Atrial myocytes were isolated from specimens of human right
atrial appendage obtained from patients receiving cardiac surgery
aging from 25 to 70 years old (male 6, female 5). After excision, the
samples were quickly immersed in oxygenated, Ca
2+-free cardio-
plegic solution for transport to the laboratory. One single atrial
myocyte was enzymatically dissociated under the sterile circum-
stance. Briefly, the atrial tissue was minced and the pieces were
digested first in a mixture of 150–200 U/ml collagenase (CLS II,
Worthington Biochemical, Freehold, NJ, U.S.A.), 1.2 U/ml
protease (type XXIV, Sigma Chemical, St Louis, MO, U.S.A.),
and 1 mg/ml bovine serum albumin (Sigma-Aldrich, St. Louis,
MO) for 50 minutes and then in a Ca
2+-free Tyrode solution with
the same composition, but without protease for about 30 minutes
after being washed three times in a Ca
2+-free Tyrode solution at
36uC and gently agitated by continuous bubbling with 100% O2.
The isolated atrial myocytes were kept in a High-K
+ storage
solution at room temperature for at least 1 hour until use.
Immunofluorescence
HEK 293 cells or human atrial myocytes were stained by
immunofluorescence for the detection of the binding of the E314
antibody to plasma membranes. After adherent cells were fixed
and blocked with 10% BSA and 1% normal donkey serum, these
cells were incubated with the E314 antibody diluted at 1:200 at
4uC overnight and then with FITC-labelled donkey anti-rabbit
secondary antibodies (Chemicon International) at room temper-
ature for 2 h away from light. The cells were observed in a
Olympus FluoView
TM FV1000 (Olympus, Japan) laser-scanning
confocal microscope. In control experiments, the primary
antibody were preincubated with an excess of E314 antigenic
peptide as a negative control.
Western blotting
To confirm the E314 antibody specific recognition, Western-
blotting analysis was performed. Human atrial or ventricular
specimens and HEK 293 cells were lysed and proteins were
extracted. Proteins were analyzed by electrophoresis in 7.5% (w/v)
polyacrylamide gel containing 0.1% (w/v) sodium dodecylsulfate
(SDS) followed by blotting to a nitrocellulose membrane. After
blocking, the membrane was incubated with the E314 antibody
diluted at 1:1000 overnight at 4uC and then incubated with
horseradish peroxidase-conjugated anti-rabbit IgG antibody 2 h at
room temperature. The blot was visualized by a chemilumines-
cence’s method (ECL Western blotting detection system). In
control experiments, the primary antibody were preincubated with
an excess of E314 antigenic peptide as a negative control.
Electrophysiological recording solution and drugs
Ca
2+-free cardioplegic solution for specimen transport con-
tained (in mM): KH2PO4 50, MgSO4 8, adenosine 5, HEPES 10,
glucose 140, mannitol 100, taurine 10, and pH was adjusted to 7.3
with KOH. High-K
+ storage solution contained (in mM): KCl 10,
K-glutamate 120, KH2PO4 10, MgSO4 1.8, taurine 10, HEPES
10, EGTA 0.5, glucose 20, mannitol 10, pH adjusted to 7.3 with
KOH. The standard Tyrode solution contained (in mM): NaCl
140, KCl 5.4, MgCl2 1, CaCl2 1, NaH2PO4 0.33, HEPES 10,
glucose 10, pH was adjusted to 7.4 with NaOH. The pipette
solution contained (in mM): KCl 20, K-aspartate 110, MgCl2 1,
HEPES 10, EGTA 5, GTP 0.1, Na2-phosphocreatine 5, and Mg-
ATP 5, pH was adjusted to 7.2 with KOH. For perforated-patch
recordings, b-escin (Sigma-Aldrich, St. Louis, MO) was added to
the pipette solution (0.042 mg/ml). For IKur recording, BaCl2
(200 mM) and CdCl2 (200 mM) were added to the superfusion to
block IK1 and ICa.L. For ICa.L recording, K
+ in pipette and Tyrode
solution was replaced by CsCl. INa was recorded under K
+-free
conditions with symmetrical Na
+ (5 mM) in pipette and superfu-
sion solutions. For IKCa3.1 the pipette solution contained (in mM):
K-aspartate 145, MgCl2 2, HEPES 10, EGTA 10, CaCl2 8.5, pH
was adjusted to 7.2 with KOH and the external solution contained
(in mM): Na-aspartate 160, KCl 4.5, CaCl2 2, MgCl2 1, HEPES 5,
pH was adjusted to 7.4 with NaOH.
Patch-clamp recording
HEK 293 cell lines, Jurkat T cells or human atrial myocytes
were incubated at least 2 h with the E314 antibody at 36uC for
total binding of the E314 antibody. Borosilicate glass electrodes
(1.2-mm OD) were constructed using a Brown-Flamming puller
(model P-97, Sutter Instrument Co, Novato, CA, USA) and had
tip resistances of 2–3 MV when filled with pipette solution for
IKv1.3,I Kv1.1,I Kv1.2,I Kv1.4,I Kv1.5,I KCa3.1,I HERG,I hKCNQ1/hKCNE1
or ICaL recording and 0.5–1 MV for INa recording. Membrane
currents were recorded using an Axopatch200B amplifier and
Clampex software (Molecular Devices, USA). For IKv1.3, IKv1.1,
IKv1.2,I Kv1.4,I Kv1.5,I KCa3.1,I HERG or INa recording, whole -cell
patch clamp was used and perforated patch configuration was
performed for IhKCNQ1/hKCNE1 or ICaL recording with additional
0.042 mg/ml Escin (Sigma-Aldrich) in the pipette solution.
Electrical signals were low-pass filtered at 5 kHz and stored on
the hard disk of computer for off-line analysis using clamfit or
sigmaplot.
Statistical Analysis
Data were expressed as mean6SEM. Statistical analysis was
performed using SPSS 12.0 software. Differences between groups
were analyzed by t test or ANOVA. P value less than 0.05 was
considered statistically significant.
Supporting Information
Figure S1 Time course of the blockage of IKv1.3 by the
E314 antibody. Time course of IKv1.3 was recorded with 250 ms
test pulses from 280 to 50 mV. The Kv1.3 currents amplitude
reduced about 55% after addition of the 300 nM E314 antibody
in 10–15 minutes and the inhibition was not reversible by
washout.
(TIF)
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